Literature DB >> 20488460

Tolerability of the dexamethasone-corticotropin releasing hormone test in major depressive disorder.

Boadie W Dunlop1, Yara Betancourt, Elisabeth B Binder, Christine Heim, Florian Holsboer, Marcus Ising, Melissa McKenzie, Tanja Mletzko, Hildegard Pfister, Charles B Nemeroff, W Edward Craighead, Helen S Mayberg.   

Abstract

BACKGROUND: The dexamethasone-corticotropin releasing hormone (Dex-CRH) test may differentially predict which depressed patients will respond to antidepressant medication. However, a comprehensive analysis of the safety of this test in psychiatric patients has not previously been performed.
METHODS: We conducted a pooled analysis of depressed patients in four clinical studies. Observed and subjectively reported side-effects in 454 patients were collected for 90 minutes following CRH administration. Pre-test electrocardiograms were available in 250 patients to assess cardiac safety. Descriptive statistics were performed to evaluate these safety data.
RESULTS: Eight-six (18.9%) subjects experienced no side-effects from the procedure. The mean number of side-effects per subject was 1.4±1.0. The most frequent adverse events were: flushing (n=216, 47.6%), feeling of warmth (144, 31.7%), hyperpnea/tachypnea (108, 23.8%), palpitations (37, 8.1%), and tachycardia (28, 6.2%). Side-effects were consistently mild and brief in duration. There were no serious adverse events.
CONCLUSION: The Dex-CRH test produces a mild, predictable side-effect profile, characterized by flushing, feelings of warmth, hyperpnea/tachypnea, palpitations, and tachycardia. These results provide reassurance that the Dex-CRH test is well tolerated in psychiatric patients. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20488460      PMCID: PMC2950910          DOI: 10.1016/j.jpsychires.2010.04.020

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  24 in total

Review 1.  The corticosteroid receptor hypothesis of depression.

Authors:  F Holsboer
Journal:  Neuropsychopharmacology       Date:  2000-11       Impact factor: 7.853

2.  Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppression.

Authors:  F Holsboer; U von Bardeleben; K Wiedemann; O A Müller; G K Stalla
Journal:  Biol Psychiatry       Date:  1987-02       Impact factor: 13.382

3.  The DEX/CRH neuroendocrine test and the prediction of depressive relapse in remitted depressed outpatients.

Authors:  Jean-Michel Aubry; Nicola Gervasoni; Christian Osiek; Guillaume Perret; Michel Florian Rossier; Gilles Bertschy; Guido Bondolfi
Journal:  J Psychiatr Res       Date:  2006-09-07       Impact factor: 4.791

4.  Regulation of the hypothalamic-pituitary-adrenocortical system in patients with panic disorder.

Authors:  Angelika Erhardt; Marcus Ising; Paul Gerson Unschuld; Nikola Kern; Susanne Lucae; Benno Pütz; Manfred Uhr; Elisabeth B Binder; Florian Holsboer; Martin E Keck
Journal:  Neuropsychopharmacology       Date:  2006-07-12       Impact factor: 7.853

5.  The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders.

Authors:  I Heuser; A Yassouridis; F Holsboer
Journal:  J Psychiatr Res       Date:  1994 Jul-Aug       Impact factor: 4.791

6.  The dexamethasone/corticotropin-releasing factor test in men with major depression: role of childhood trauma.

Authors:  Christine Heim; Tanja Mletzko; David Purselle; Dominique L Musselman; Charles B Nemeroff
Journal:  Biol Psychiatry       Date:  2007-09-07       Impact factor: 13.382

7.  HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients.

Authors:  E B Binder; H E Künzel; T Nickel; N Kern; A Pfennig; M Majer; M Uhr; M Ising; F Holsboer
Journal:  Psychoneuroendocrinology       Date:  2008-09-30       Impact factor: 4.905

8.  Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo.

Authors:  K Karalis; H Sano; J Redwine; S Listwak; R L Wilder; G P Chrousos
Journal:  Science       Date:  1991-10-18       Impact factor: 47.728

9.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

10.  Human corticotropin-releasing hormone improves overnight FEV1 in nocturnal asthma.

Authors:  G Georges; M Kraft; E O Vianna; R J Martin
Journal:  J Asthma       Date:  1998       Impact factor: 2.515

View more
  4 in total

Review 1.  Metabotropic Glutamate Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy.

Authors:  Samuel A Barnes; Douglas J Sheffler; Svetlana Semenova; Nicholas D P Cosford; Anton Bespalov
Journal:  Biol Psychiatry       Date:  2018-03-09       Impact factor: 13.382

2.  Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial.

Authors:  Boadie W Dunlop; Elisabeth B Binder; Joseph F Cubells; Mark M Goodman; Mary E Kelley; Becky Kinkead; Michael Kutner; Charles B Nemeroff; D Jeffrey Newport; Michael J Owens; Thaddeus W W Pace; James C Ritchie; Vivianne Aponte Rivera; Drew Westen; W Edward Craighead; Helen S Mayberg
Journal:  Trials       Date:  2012-07-09       Impact factor: 2.279

3.  The Cortisol and ACTH Response to Dex/CRH Testing in Women With and Without Perimenopausal Depression.

Authors:  Gioia M Guerrieri; Rivka Ben Dor; Xiaobai Li; Shau-Ming Wei; Pedro E Martinez; Lynnette K Neiman; David R Rubinow; Peter J Schmidt
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 6.134

4.  Protocol for a randomised, double-blind, placebo-controlled trial to explore the effect of tramadol in the prevention of postpartum depression (ETPPD).

Authors:  Guangyou Duan; Zhuoxi Wu; Peng Zhao; Jing Peng; Zhengqiong Chen; Qingling Zhang; Rufu Xu; Hong Li
Journal:  BMJ Open       Date:  2018-10-21       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.